Resistance to rapamycin: A novel anticancer drug

Shile Huang, Peter J. Houghton

Research output: Contribution to journalArticlepeer-review

46 Scopus citations


The macrocyclic lactone rapamycin has an established place as an immune suppressive agent in organ transplantation. However, more recently it has been recognized as an inhibitor of pathways that may be activated during malignant transformation and tumor progression. Thus, increasing interest is being directed to this class of antibiotic as potential antitumor agents. Here we summarize the history, mechanism of action, and mechanisms of resistance to rapamycin.

Original languageEnglish (US)
Pages (from-to)69-78
Number of pages10
JournalCancer and Metastasis Reviews
Issue number1-2
StatePublished - 2001
Externally publishedYes


  • Apoptosis
  • Cancer
  • Cell cycle
  • Cell proliferation
  • Rapamycin
  • Resistance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Resistance to rapamycin: A novel anticancer drug'. Together they form a unique fingerprint.

Cite this